title: Azelnidipine and amlodipine anti-coronary atherosclerosis trial in hypertensive patients undergoing coronary intervention by serial volumetric intravascular ultrasound analysis in Juntendo university (ALPS-J).
abstract: OBJECTIVE
  Many trials have shown that calcium channel blockers (CCBs) can reduce the cardiovascular (CV) events in patients with coronary artery disease (CAD). The mechanisms of this effect could be associated with plaque regression due to the anti-atherosclerotic properties of CCBs. The goal of this study is to determine the effects of CCB on volumetric quantitative changes of coronary plaques accessed by intravascular ultrasound (IVUS). To confirm this hypothesis, a multicenter randomized trial of CCBs treatment with azelnidipine or amlodipine will be conducted in hypertensive CAD patients undergoing elective percutaneous coronary intervention (PCI).
  
  
  RESULTS
  Patients who have hypertension and are scheduled for PCI will be enrolled. Subjects will be randomized to azelnidipine or amlodipine and observed for 48 weeks. The primary endpoint will be the percent change of coronary plaque volume. The secondary endpoint will include inflammatory markers, antioxidant activity, and incidence of composite cardiovascular events.
  
  
  CONCLUSIONS
  In this study, we will investigate the improvement of coronary plaque with IVUS by treatment with two dihydropyridine CCBs in hypertensive patients undergoing elective PCI. This result will lead to the discovery of more effective drug therapy for inhibition of coronary events.
authors.affiliation: Department of Cardiology, Juntendo University School of Medicine, Tokyo, Japan.
authors.forename: Katsumi
authors.initials: K
authors.lastname: Miyauchi
authors.forename: Takahiko
authors.initials: T
authors.lastname: Kojima
authors.forename: Takayuki
authors.initials: T
authors.lastname: Yokoyama
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kurata
authors.forename: Ken
authors.initials: K
authors.lastname: Yokoyama
authors.forename: Masaki
authors.initials: M
authors.lastname: Kawamura
authors.forename: Satoru
authors.initials: S
authors.lastname: Suwa
authors.forename: Shinya
authors.initials: S
authors.lastname: Okazaki
authors.forename: Kenji
authors.initials: K
authors.lastname: Inoue
authors.forename: Yasumasa
authors.initials: Y
authors.lastname: Fujiwara
authors.forename: Masataka
authors.initials: M
authors.lastname: Sumiyoshi
authors.forename: Kosei
authors.initials: K
authors.lastname: Tanimoto
authors.forename: Yuji
authors.initials: Y
authors.lastname: Nakazato
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Yamagami
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Daida
mesh_terms: D000328:Adult; D000368:Aged; D017311:Amlodipine / Q000009:adverse effects / Q000627:therapeutic use*; D001383:Azetidinecarboxylic Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000627:therapeutic use*; D003324:Coronary Artery Disease / Q000150:complications / Q000000981:diagnostic imaging* / Q000517:prevention & control*; D004095:Dihydropyridines / Q000009:adverse effects / Q000627:therapeutic use*; D018450:Disease Progression; D004311:Double-Blind Method; D023381:Endpoint Determination; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D014463:Ultrasonography; D055815:Young Adult
chemical_list: D002121:Calcium Channel Blockers; D004095:Dihydropyridines; D017311:Amlodipine; D001383:Azetidinecarboxylic Acid; C061679:azelnidipine